Morgan Stanley lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.14 from $3 and keeps an Equal Weight rating on the shares. The firm is updating its model for Akoya’s Q1 results and the amended merger agreement proposed by Quanterix (QTRX), the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Cautious Outlook for Akoya Biosciences Amidst Competitive Pressures and Promising Long-Term Potential
- Akoya Biosciences Reports Q1 2025 Financial Results
- Akoya Biosciences price target lowered to $1.08 from $1.80 at Canaccord
- Cautious Hold Rating on Akoya Biosciences Amid Financial and Industry Challenges
- Quanterix price target lowered to $12 from $15 at Canaccord